Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)
Fast, easy summary view of NICE guidance on 'dementia'
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically:
- donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and
- memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.
- TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: dementia
This page was last updated: 12 February 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA217 Donepezil, galantamine, rivastigmine a memantine ar gyfer clefyd Alzheimer: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.